Arcellx, Inc.
ACLX
Κατάταξη σε μετοχές
#2786
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Τιμή μετοχής
$115.07
Τελευταίος συγχρονισμός: 2026-05-15
Κεφαλαιοποίηση
$6.73B
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
32.61%
Χώρα
US
Εμπόριο Arcellx, Inc. (ACLX)
Κατηγορία
Healthcare
Δείκτης P/S για Arcellx, Inc. (ACLX)
Δείκτης P/S στις October 2026 TTM: 475.55
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή μετοχής της Arcellx, Inc., ο τρέχων δείκτης P/S (TTM) είναι 475.55. Στο τέλος του 2023, ο δείκτης ήταν 24.18.
Ιστορικό P/S για την Arcellx, Inc. από 2018 έως 2026
Δείκτης P/S στο τέλος κάθε έτους
| Έτος | P/S Ratio | Αλλαγή |
|---|---|---|
| 2026 (TTM) | 475.55 | 1,149.47% |
| 2024 | 38.06 | 57.41% |
| 2023 | 24.18 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Δείκτης P/S για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | P/S Ratio | Διαφορά P/S Ratio | Χώρα |
|---|---|---|---|
| 10.02 | -97.89% |
US
|
|
| 40.55 | -91.47% |
US
|
|
| 3.96 | -99.17% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -97.87% |
NL
|
